ロード中...
Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management
Immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4 antibodies) are a standard of care for advanced melanoma. Novel toxicities comprise immune-related adverse events (irAE). With increasing use, irAE require recognition, practical management strategies, and multidisciplinary care. We retrospecti...
保存先:
| 出版年: | J Skin Cancer |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Hindawi
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5828308/ https://ncbi.nlm.nih.gov/pubmed/29610684 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/9602540 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|